[go: up one dir, main page]

WO2015100370A3 - Formulations de dépôt à libération prolongée de protéines thérapeutiques, et utilisations correspondantes - Google Patents

Formulations de dépôt à libération prolongée de protéines thérapeutiques, et utilisations correspondantes Download PDF

Info

Publication number
WO2015100370A3
WO2015100370A3 PCT/US2014/072253 US2014072253W WO2015100370A3 WO 2015100370 A3 WO2015100370 A3 WO 2015100370A3 US 2014072253 W US2014072253 W US 2014072253W WO 2015100370 A3 WO2015100370 A3 WO 2015100370A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic proteins
depot formulations
sustained release
release depot
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/072253
Other languages
English (en)
Other versions
WO2015100370A2 (fr
Inventor
Shawn P. Iadonato
Ernesto J. MUNOZ
James CHESKO
Eric J. Tarcha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kv1.3 Therapeutics Inc
Original Assignee
Kineta One LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta One LLC filed Critical Kineta One LLC
Priority to EP14875392.4A priority Critical patent/EP3086779A4/fr
Priority to CN201480069029.3A priority patent/CN105873570A/zh
Priority to JP2016533693A priority patent/JP2017501980A/ja
Priority to US15/107,355 priority patent/US20160338967A1/en
Publication of WO2015100370A2 publication Critical patent/WO2015100370A2/fr
Publication of WO2015100370A3 publication Critical patent/WO2015100370A3/fr
Priority to IL246408A priority patent/IL246408A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des formulations de dépôt comportant des protéines thérapeutiques. Lesdites protéines thérapeutiques peuvent se présenter sous la forme de protéines thérapeutiques fondées sur des toxines. Les formulations de dépôt libèrent la protéine thérapeutique à des taux effectifs prolongés pendant au moins un mois après une administration unique. Les protéines thérapeutiques fondées sur des toxines peuvent comprendre des protéines fondées sur des ShK.
PCT/US2014/072253 2013-12-23 2014-12-23 Formulations de dépôt à libération prolongée de protéines thérapeutiques, et utilisations correspondantes Ceased WO2015100370A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP14875392.4A EP3086779A4 (fr) 2013-12-23 2014-12-23 Formulations de dépôt à libération prolongée de protéines thérapeutiques, et utilisations correspondantes
CN201480069029.3A CN105873570A (zh) 2013-12-23 2014-12-23 治疗性蛋白质的持续释放储槽式调配物和其用途
JP2016533693A JP2017501980A (ja) 2013-12-23 2014-12-23 治療タンパク質の徐放型デポー製剤、およびその使用
US15/107,355 US20160338967A1 (en) 2013-12-23 2014-12-23 Sustained release depot formulations of therapeutic proteins, and uses thereof
IL246408A IL246408A0 (en) 2013-12-23 2016-06-22 Preparations for delayed release of proteins and their uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920383P 2013-12-23 2013-12-23
US61/920,383 2013-12-23

Publications (2)

Publication Number Publication Date
WO2015100370A2 WO2015100370A2 (fr) 2015-07-02
WO2015100370A3 true WO2015100370A3 (fr) 2015-08-20

Family

ID=53479787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/072253 Ceased WO2015100370A2 (fr) 2013-12-23 2014-12-23 Formulations de dépôt à libération prolongée de protéines thérapeutiques, et utilisations correspondantes

Country Status (6)

Country Link
US (1) US20160338967A1 (fr)
EP (1) EP3086779A4 (fr)
JP (1) JP2017501980A (fr)
CN (1) CN105873570A (fr)
IL (1) IL246408A0 (fr)
WO (1) WO2015100370A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013814B2 (en) 2017-03-16 2021-05-25 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof
US11090358B2 (en) 2015-09-09 2021-08-17 Fred Hutchinson Cancer Research Center Cartilage-homing peptides

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140038501A (ko) * 2011-06-06 2014-03-28 키네타 원, 엘엘씨 Shk-기초된 제약학적 조성물 및 이들을 제조하고 이용하는 방법
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090263462A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods for Treating Conditions Such as Dystonia and Post-Stroke Spasticity with Clonidine
US20110163469A1 (en) * 2005-12-16 2011-07-07 Massachusetts Institute Of Technology High-throughput fabrication of microparticles
US8080523B2 (en) * 2004-10-07 2011-12-20 The Regents Of The University Of California Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2699692T3 (es) * 2010-01-04 2019-02-12 Mapi Pharma Ltd Sistema de depósito que comprende acetato de glatiramer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080523B2 (en) * 2004-10-07 2011-12-20 The Regents Of The University Of California Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
US20110163469A1 (en) * 2005-12-16 2011-07-07 Massachusetts Institute Of Technology High-throughput fabrication of microparticles
US20090263462A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods for Treating Conditions Such as Dystonia and Post-Stroke Spasticity with Clonidine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090358B2 (en) 2015-09-09 2021-08-17 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
US11648290B2 (en) 2015-09-09 2023-05-16 Fred Hutchinson Cancer Center Cartilage-homing peptides
US11013814B2 (en) 2017-03-16 2021-05-25 Blaze Bioscience, Inc. Cartilage-homing peptide conjugates and methods of use thereof

Also Published As

Publication number Publication date
EP3086779A2 (fr) 2016-11-02
IL246408A0 (en) 2016-08-31
WO2015100370A2 (fr) 2015-07-02
JP2017501980A (ja) 2017-01-19
CN105873570A (zh) 2016-08-17
EP3086779A4 (fr) 2017-12-13
US20160338967A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
CA2956871C (fr) Composes actifs envers des bromodomaines
EP3736282C0 (fr) Peptide de pénétration cellulaire, conjugué le comprenant, et composition comprenant le conjugué
CA2883095C (fr) Anticorps et formulations proteiques
IL249830A0 (en) Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof
EP3597735A4 (fr) Anticorps ctla4, composition pharmaceutique et leur utilisation
EP3491026A4 (fr) Anticorps humains, compositions pharmaceutiques et procédés
HK1218621A1 (zh) 用於治疗慢性炎症和炎性疾病的组合物及方法
WO2015023649A3 (fr) Peptides destinés à améliorer l'administration transdermique
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
HK1217650A1 (zh) 用於治疗剧痛的组合物及方法
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
AU2016289474B2 (en) HBED-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents
EP4331622A3 (fr) Peptides de liaison à l'intégrine et leurs utilisations
MY183068A (en) Pharmaceutical formulation comprising antibody
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
WO2015100370A3 (fr) Formulations de dépôt à libération prolongée de protéines thérapeutiques, et utilisations correspondantes
EP3263584A4 (fr) Peptide pour cibler les cellules autophagiques et utilisation de ce dernier
EP3291818A4 (fr) Compositions et procédés pour l'administration d'agents thérapeutiques dans le côlon
EP3399990A4 (fr) Compositions thérapeutiques contenant des peptides et leurs utilisations
EP3262047A4 (fr) Dérivé d'imidazopyrimidine et d'imidazotriazine, et composition pharmaceutique le comprenant
SG11202103806VA (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
PH12017501979A1 (en) Pharmaceutical compound
HK40097408A (en) Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
HK40101439A (en) Gene construct, expression vector, pharmaceutical composition and the use thereof
EP3258956A4 (fr) Dldh, dérivés de ceux-ci et formulations les comprenant pour une utilisation en médecine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14875392

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2016533693

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15107355

Country of ref document: US

Ref document number: 246408

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2014875392

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014875392

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14875392

Country of ref document: EP

Kind code of ref document: A2